The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Multiple Myeloma

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2020 Jul 15

PMID 32661116

Citations 16

Authors

Nina Shah

Jack Aiello

David E Avigan

Jesus G Berdeja

Ivan M Borrello

Ajai Chari

Adam D Cohen

Karthik Ganapathi

Lissa Gray

Damian Green

Amrita Krishnan

Yi Lin

Elisabet Manasanch

Nikhil C Munshi

Ajay K Nooka

Aaron P Rapoport

Eric L Smith

Ravi Vij

Madhav Dhodapkar

Affiliations

Soon will be listed here.

Abstract

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Citing Articles

Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia.

Ho P, Quach H, Sidiqi M, Lee C, Butler J, Spencer A Front Oncol. 2025; 14:1535869.

PMID: 39906669 PMC: 11790593. DOI: 10.3389/fonc.2024.1535869.

Efbalropendekin Alfa enhances human natural killer cell cytotoxicity against tumor cell lines .

Shehata H, Dogra P, Gierke S, Holder P, Sanjabi S Front Immunol. 2024; 15:1341804.

PMID: 38515757 PMC: 10954783. DOI: 10.3389/fimmu.2024.1341804.

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.

Robinson M, Villa N, Jaye D, Nooka A, Duffy A, McCachren S J Clin Invest. 2023; 133(15).

PMID: 37526080 PMC: 10378152. DOI: 10.1172/JCI167629.

Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma.

Peat T, Gaikwad S, Dubois W, Gyabaah-Kessie N, Zhang S, Gorjifard S Cancer Lett. 2023; 568:216284.

PMID: 37356470 PMC: 10408729. DOI: 10.1016/j.canlet.2023.216284.

Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy.

Russell B, Avigan D Int J Hematol. 2023; 117(5):652-659.

PMID: 36964840 PMC: 10039687. DOI: 10.1007/s12185-023-03579-x.

References

Baeuerle P, Reinhardt C . Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009; 69(12):4941-4. DOI: 10.1158/0008-5472.CAN-09-0547. View

Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2007; 111(5):2521-6. DOI: 10.1182/blood-2007-08-104984. View

Facon T, Kumar S, Plesner T, Orlowski R, Moreau P, Bahlis N . Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019; 380(22):2104-2115. PMC: 10045721. DOI: 10.1056/NEJMoa1817249. View

Perrot A, Corre J, Avet-Loiseau H . Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside. Am Soc Clin Oncol Educ Book. 2018; 38:675-680. DOI: 10.1200/EDBK_200879. View

Boyiadzis M, Bishop M, Abonour R, Anderson K, Ansell S, Avigan D . The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMC: 5168808. DOI: 10.1186/s40425-016-0188-z. View

Mateos M, Granell M, Oriol A, Martinez-Lopez J, Blade J, Hernandez M . Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2016; 175(3):448-456. DOI: 10.1111/bjh.14263. View

Rocchi S, Tacchetti P, Pantani L, Mancuso K, Zannetti B, Cavo M . Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma. Haematologica. 2018; 103(6):e277-e278. PMC: 6058770. DOI: 10.3324/haematol.2018.191122. View

Tai Y, Mayes P, Acharya C, Zhong M, Cea M, Cagnetta A . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-38. PMC: 4023420. DOI: 10.1182/blood-2013-10-535088. View

Nooka A, Wang M, Yee A, Kaufman J, Bae J, Peterkin D . Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018; 4(12):e183267. PMC: 6440721. DOI: 10.1001/jamaoncol.2018.3267. View

10.

Klippel Z, Chou J, Towlerton A, Voong L, Robbins P, Bensinger W . Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC. Gene Ther. 2014; 21(3):337-42. PMC: 4040020. DOI: 10.1038/gt.2013.87. View

11.

Jakubowiak A, Offidani M, Pegourie B, Rubia J, Garderet L, Laribi K . Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016; 127(23):2833-40. PMC: 4900953. DOI: 10.1182/blood-2016-01-694604. View

12.

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

13.

Jain T, Litzow M . No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv. 2018; 2(22):3393-3403. PMC: 6258912. DOI: 10.1182/bloodadvances.2018020198. View

14.

. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2018; 93(8):981-1114. PMC: 6223128. DOI: 10.1002/ajh.25117. View

15.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

16.

Kazandjian D, Landgren O . A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival. Semin Oncol. 2017; 43(6):682-689. PMC: 5282737. DOI: 10.1053/j.seminoncol.2016.10.008. View

17.

Fried S, Avigdor A, Bielorai B, Meir A, Besser M, Schachter J . Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019; 54(10):1643-1650. DOI: 10.1038/s41409-019-0487-3. View

18.

Magen H, Muchtar E . Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016; 7(4):187-95. PMC: 4959642. DOI: 10.1177/2040620716652862. View

19.

Kumar S, Rajkumar S, Dispenzieri A, Lacy M, Hayman S, Buadi F . Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2007; 111(5):2516-20. PMC: 2254544. DOI: 10.1182/blood-2007-10-116129. View

20.

Chou C, Turtle C . Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Transplant. 2019; 54(Suppl 2):780-784. DOI: 10.1038/s41409-019-0602-5. View